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The long asymptomatic stage of HIV infection poses a great challenge in identifying recent HIV infections. This is a bottle-
neck for monitoring HIV epidemic trends and evaluating the effectiveness of national AIDS control programs. Several sero-
logical methods were used to address this issue with some success. Because of high false-positive rates in patients with ad-
vanced infection or in ART treatment, UNAIDS still hesitates to recommend their use in routine surveillance. We developed a 
new pattern-based method for measuring intra-patient viral genetic diversity for determination of recent infections and estima-
tion of population incidence. This method is verified by using several datasets (424 subtype B and 77 CRF07_BC samples) 
with clearly identified HIV-1 infection times. Pattern-based diversities of recent infections are significantly lower than that of 
chronic ones. With larger window periods varying from 200 to 350 days, a higher accuracy (90%95%) not affected by ad-
vanced disease nor ART treatment could be obtained. The pattern-based genetic method is supplementary to the existing se-
rology-based assays, both of which could be suitable for use in low and high epidemic regions, respectively. 
determination of HIV recent infections, estimation of population incidence, viral genetic diversity, pattern-based dis-
tance 
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Since the acquired immune deficiency syndrome (AIDS) 
caused by the human immunodeficiency virus type 1 
(HIV-1) was identified 30 years ago, the pandemic has re-
sulted in extremely heavy human costs of over 60 million 
infections, including nearly 30 million deaths worldwide. 
Understanding the current state and future trends of HIV-1 
infection is essential to halt the AIDS epidemic [1]. How-
ever, the very long asymptomatic stage of HIV infection 
poses a great challenge in identifying recent HIV infections, 
and is a bottleneck for both monitoring HIV epidemic 
trends and evaluating the effectiveness of national AIDS 
control programs. Therefore, HIV-1 incidence has never 
been correctly estimated in a timely fashion, although vari-
ous strategies have been applied to address this problem. 
For instance, the Joint United Nations Program on 
HIV/AIDS (UNAIDS) decreased their previous estimates of 
the worldwide annual HIV-1 incidence by 42%, whereas the 
CDC of the United States increased theirs by 40% [2]. 
Without such critical information, the public health agencies 
are unable to determine the rising HIV/AIDS case reports at 
the end of the year due to improvement of the reporting 
system, or more new infections.   
An ideal way to monitor epidemic trends is to determine  
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infection duration of individual carriers/patients from their 
blood samples, which can be collected with ease. In partic-
ular, a huge pool of existing samples can be used to trace 
historical epidemic trends. In the past decade, many scien-
tists worked on various serological methods to identify re-
cent HIV-1 infections, named Serological Testing Algo-
rithms for Recent HIV Seroconversion (STARHS) [36]. 
The most widely used STARHS method is the one devel-
oped by the US CDC: the BED HIV-1 capture enzyme im-
munoassay. The BED is based on measuring the ratio of 
anti-HIV IgG to the total IgG in the blood, with a measura-
ble window of 153 days (the increasing linear curve during 
acute HIV infection). The BED assay had been used in the 
field in many developed and developing countries, espe-
cially after release of the US national HIV incidence esti-
mate [1]. However, its performance was not satisfactory, 
with unacceptably high false-positive rates due to a drop in 
specificity in both the late stage of HIV infection (AIDS) 
and antiviral treatment. The UNAIDS HIV incidence study 
task force recommended the BED should not be used in rou-
tine surveillance, or in absolute incidence estimates [7–9]. 
Thus, there is an urgent need to improve the current assays 
and provide complimentary methodology to overcome this 
obstacle. 
It has been known for some time that viral genetic diver-
sity in newly infected persons is much lower than in chronic 
infections [1015], but no systematic effort had been con-
ducted to distinguish recent from chronic HIV infection by 
measuring HIV genetic diversity. First of all, the HIV viral 
gene actively undergoes variations in many ways, including 
point mutations (annual mutation rate of about 1% for the 
env gene), insertions and deletions, which result in a small 
mean value difference between recent and chronic infection, 
and large deviation within each category. Second, about one 
quarter to one third of the subjects are infected by more than 
one founder virus [16], which can cause confusion about the 
molecular clock of HIV infection duration. All these aspects 
make it difficult to use the HIV genetic diversity as a relia-
ble estimator. Here, we developed a novel methodology by 
carefully combining suitable tools of HIV-1 genetic diver-
sity measurement and statistical method to overcome the 
previously mentioned challenges. The new algorithm was 
validated using a panel of datasets with clearly-defined HIV 
infection time available in the international database (sub-
type B dataset) and by our own cohort study (CRF07_BC 
dataset). The new methodology is shown to be able to detect 
recent HIV infection with high accuracy (above 90%) in 
patients with both early and advanced stages of infections. 
Therefore, this new methodology has the potential to be 
used as a complementary method to serology-based assays, 
such as BED, and provide the combined tools to public 
health agencies for identifying recent HIV infections and 
monitoring AIDS epidemic trends.  
1  Materials and methods 
1.1  Data collection 
1.1.1  Subtype B dataset 
A total of 424 samples of 257 subtype B subjects were se-
lected from the CHAVI, MACS, Seattle primary infection 
cohort, MGH cohort, Women’s HIV Interdisciplinary Net-
work, and other projects. Selection criteria were: (i) Patients 
were from a longitudinal cohort or diagnosed with HIV in-
fections more than one year ago. (ii) Viral loads were more 
than 50 copies mL1 (range: 300106). (iii) More than ten 
sequences in the env C2V5 region (length about 180 ami-
no acids) are available in the sequence database and quality 
control measures were used in the experimental procedure 
for deriving the sequence from plasma samples to ensure 
that the sequences of a sample were representative of the 
HIV-1 population in vivo. All the C2V5 env sequences of 
these samples were collected from the Los Alamos HIV 
database. The window period to classify recent versus 
chronic infection was defined as 200 days after seroconver-
sion. The database editors suggested that the labeled num-
ber of days were mostly estimates. Therefore, we went back 
to the original papers to confirm the study-specific timing 
definitions. When sequences were labeled as Fiebig Stages 
IV (infected less than 100 days), samples were called “re-
cent infections”. Fiebig Stage VI was excluded. Of all sam-
ples, 160 were regarded as recent infections and the re-
maining 264 as chronic infections, details are provided in 
Appendix Tables 13 in the electronic version. 
1.1.2  Subtype CRF07_BC dataset 
A total of 77 plasma samples were used that were previous-
ly collected from 27 drug naïve HIV-1 infected individuals 
in the HPTN033 program [18]. The window period to clas-
sify recent versus chronic infection was defined as 365 days 
after seroconversion. Of all samples, 21 were regarded as 
recent infections, and the remaining 56 as chronic infections. 
Sequences for the calculation of the intra-patient viral ge-
netic diversity were derived from about 280 collected plas-
ma samples by the SGA method [16,19]. Details are pro-
vided in Appendix Table 4. The nucleotide sequences from 
this study are available in GenBank under accession number 
HQ668526-HQ668930, HQ668941-HQ668974，HQ668984- 
HQ669461, and HQ669468-HQ670224. 
RNA templates were extracted from 280 µL plasma using 
the QIAamp Viral RNA Mini kit (Qiagen, Hilden, Germa-
ny), and eluted with 60 µL elution buffer. The cDNAs were 
then synthesized by an oligo (dT) primer using the Super-
Script III first-strand synthesis system kit (Invitrogen; 
Carlsbad, California, USA). In brief, 25 µL reaction mixture 
with 20 µL RNA template, 2.5 µmol L1 primer oligo (dT) 
and 0.5 mmol L1 dNTPs were denatured at 65°C for 5 min. 
Then the 25 µL cDNA synthesis mixture containing 1 re- 
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verse transcription buffer, 5 mmol L1 MgCl2, 10 mmol L
1 
DTT, 2 units µL1 RNaseOUT and 10 units µL1 Super-
Script III reverse transcriptase, were added into the reaction 
mixture and incubated at 50°C for 50 min. The reaction was 
terminated at 85°C for 5 min and RNase H was added to 
remove the RNA template at 37°C for 20 min. The resulting 
cDNA was used immediately or stored at 20°C for further 
use. 
The single genome amplification (SGA) of the env 
V1V5 fragment was performed as previously described 
[16,19]. Briefly, the serial diluted cDNA templates (1:5 to 
1:45) distributed among wells of replicate 96-well plates 
were amplified to identify the optimal dilution with no more 
than 30% of positive wells.  
The first round PCR amplification was carried out in 25 
µL mixture containing 1.5 µL cDNA dilutions, 0.2 µmol L1 
primer F1X (5′-GATGGATGAGGATGTAATCAGTTTA- 
TGGGA-3′, HXB2: 6533-6562) and R1X (5′-ATTGACGC- 
YGCGCCCATAGTGCT-3′, HXB2: 7828-7806), and 12.5 
µL Premix Ex Taq (Takara Bio Inc., Tokyo, Japan). The 
PCR thermo-cycling profiles are 94C for 3 min followed 
by 35 cycles of 94C for 30 s, 62C with a decrement of 
0.3°C per cycle for 30 s, 72C for 1 min 30 s; with a final 
extension of 72C for 10 min. The second round PCR was 
performed in 25 µL mixture containing 1.5 µL first round 
products, 0.2 µmol L1 primer F2X (5′-AGTTTATG- 
GGATCAAAGCCTAAAGCCATGT-3′, HXB2: 6552-6581) 
and R2X (5′-GCTCTTTTTTCTCTCTCCACCACTCT- 
CCT-3′, HXB2: 7759-7731). The PCR conditions were as 
follows: 94C for 3 min followed by 30 cycles of 94C for 
30 s, 55C for 30 s, 72C for 1 min 30 s; with a final exten-
sion of 72C for 10 min. The PCR products were inspected 
using the 1% Pre-cast E-Gel 96 (Invitrogen).  
To avoid inter-specimen contamination for the massive 
operation in the amplification procedures, and to reduce the 
labor intensity in serial dilution and single genome amplifi-
cation, the JANUS Automated Workstation (PerkinElmer, 
Waltham, Massachusetts, USA) was used to setup the PCR 
reaction, to perform the serial dilution, and to distribute the 
reagent and first round templates for determining both op-
timal dilution for SGA and following SGA experiments. 
The second round PCR templates were added into the reac-
tion mixture using multichannel pipettes manually. 
The PCR products were purified using the QIAquick 
PCR Purification kit (Qiagen, Hilden, Germany) and di-
rectly sequenced in both directions using an ABI 3100 Ge-
netic Analyzer (BigDye V3.1; Applied Biosystems, Foster 
City, California, USA). The sequences for each amplicon 
were assembled and cleaned with a Sequencher V4.9 (Gene 
Codes, USA). Any sequence with evidence of mixed bases 
was excluded from further analysis. Finally, the 10 to 39 
sequences were obtained from each sample. 
The BED assay was performed following the manufac-
turer’s instructions (Calypte, Portland, Oregon, USA). The 
specimens with a normalized optical density less than 0.8 
were classified as recent infections. 
1.2  Definition of diversity 
Here we define a new pair-wise distance to measure the 
genetic diversity. For a given sequence of length L, a seg-
ment of length k is designated as a k-mer (a test run shows 
that k=14 is the suitable word length for the dataset used in 
this work). The number of such k-mers (denoted as N) can 
be determined by sequentially searching the sequence step 
by step, such that 
 N=Lk+1. (1) 
Given two sequences A and B, k-mers derived from se-
quence A are referred to as “A k-mers”. The genetic distance 
from sequence A to sequence B is determined by the number 
of “A k-mers” appearing in sequence B. Thus, the normal-
ized pair-wise distance from sequence A to sequence B 















where ( )ABN  is the number of “A k-mers” appearing in se-
quence B.  
Since it is likely that some k-mers will be repeated within 
a given sequence, the value of DA→B is possibly different 
from that of DA→B, so that the diversity is defined as the av-




















where m is the number of viral sequences per sample at a 
given time.  
1.3  Sequence length requirements 
While using full-length gp120 sequences will clearly give 
the most reliable and accurate estimates of infection dura-
tion, it would also increase the cost of the method. To re-
duce the cost of the method as much as possible, we ana-
lyzed the effect of sequence length on accuracy.  
Since the diversity has normalized values ranging from 0 
to 1, independent of sequence length, changes in sequence 
length affect the variance. Longer gp120 sequences result in 
more consistent numbers of mutations occurring in each 
sequence, resulting in a smaller variance. According to the 
binomial distribution, the probability (p) of at least one mu-
tation occurring per year in a sequence is as follows: 
 1.0 (1.0 ) ,np a    (4) 
 Yang J, et al.   Sci China Life Sci   April (2012) Vol.55 No.4 331 
where a (102 mutations/site/year) is the replication error 
frequency and n is the sequence length. According to eq. (4), 
about 180 amino acids (C2V5) is a suitable length for high 
accuracy.  
1.4  Sequences per sample requirement 
According to eq. (3) the change of intra-patient diversity is 
a function of the number of sequences with occurring muta-
tion. If more than one half of the sampled sequences (de-
noted as m) were with at least one mutation occurring after 
the window period, this sample could be identified as 
chronic infection. The probability (Pr) of more than one half 
of the sampled sequences occurring with at least one muta-
tion could be calculated by the binomial distribution:  
 
/2
Pr( / 2) (1 ) ,
m
i i m i
m
i m
i m C p p 

    (5) 
where im/2,..., m represents the number of sequences oc-
curring with at least one mutation, imC  denotes the number 
of combinations of m things taken i, p=0.85 is the probabil-
ity of at least one mutation occurring (calculated by eq. (4)). 
According to eq. (5), more than 10 sequences per sample 
are necessary to accurately identify recent infection. 
1.5  Accuracy measurements 
We defined “recent infections” as true positives and 
“chronic infections” as true negatives. The accuracy (Ac) is 









where TP is the number of positive cases that were correctly 
identified, TN is the number of negative cases that were 
correctly rejected, FP is the number of over-identified cases, 
and FN is the number of under-identified cases. 
In addition, other general parameters that are used in 
most other studies were applied. These included sensitivity 
(Sn), specificity (Sp), predicted positive value (PPV), and 
predicted negative value (NPV), which were defined as fol-
lows: 
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1.6  Estimating the number of the recent infections in a 
dataset  
Assume that N0 and N1 samples are identified as recent in-
fections and chronic infections in a dataset, respectively. 
Since the number of false negatives and false positives 
could often not cancel each other out, the number of recent 
infections ( 0N  ) in the dataset should be adjusted as 
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 (8) 
The uncertain interval (95% CI) in eq. (8), ∆, is the function 
of parameters, PPV, NPV, the rate of recent infection in a 
dataset and the sample size of the dataset (N0+N1). The 
sample size required for high accuracy with accepted rela-
tive uncertain interval could be estimated by eq. (8).  
2  Results 
2.1  Identifying recent infection in the subtype B da-
taset 
Samples in the subtype B dataset were derived from a dif-
ferent cohort study. The detailed information of subjects 
from each cohort are summarized in Table 1. The pat-
tern-based diversity value (D) of each sample in the subtype 
B dataset was calculated from the available C2V5 se-
quences of the env gene and was plotted in Figure 1A and B 
and summarized in Appendix Tables 13 in the electronic 
version. With a window period of 200 d, the mean values 
(standard deviation) were D0=0.08 (S0=0.10) for the recent 
infections, D1=0.48 (S1=0.16) for chronic infections, show-
ing a statistically significant difference (P<0.001). More- 
over, the average diversities of chronic infections from 55 
samples of antiretroviral-treated patients and 89 samples of 
untreated patients were 0.48 and 0.52, respectively, showing 
a statistically insignificant difference (P=0.13). The influ-
ence of CD4 counts (range: 27195) on diversity were also 
statistically insignificant. The average diversities of chronic 
infections from 25 samples of <200 CD4 counts, 33 samples 
of 200500 CD4 counts and 40 samples of >500 CD4 
counts were 0.47, 0.47 and 0.58, respectively (P=0.43).  
It has been reported that about one quarter to one third of 
the subjects are infected by more than one founder [12]. In 
the subtype B dataset, 32 recent infections are documented 
to be infected by multiple founders [16], diversity values of 
which are larger than that infected by one founder. Simply 
using the diversity values as an estimator, about 7 of 32 
were identified as chronic infections. To differentiate the 
recent infections of multiple founders from chronic ones, 
we analyzed the CV values of diversity (standard deviation 
of pair-wise distance/diversity), showing that the CV values 
of the chronic infections approximately follow a normal 
distribution, while that of the recent infections do not. The 
CV value could not be used to identify recent versus chronic 
infections because of the high false negative rate, but could  
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Table 1  Information of samples in different cohortsa) 
Subtype Cohort 




IDU MSM Hetero Other <200 d 201365 d >1 years 
B 
MACS 0 78 0 1 16.7 5 4 70 79 
CHAVI 1 36 34 77 26.2 118 0 30 148 
WHIN 2 0 21 1 15.2 0 0 24 24 
SPIC 0 15 0 0 21.2 2 0 13 15 
MGH 0 10 0 0 23.5 0 0 10 10 
Others 35 54 7 52 19.2 35 5 108 148 
B’C HPTN033 73 4 0 0 21.7 12 9 56 77 
 Total 111 197 62 131 21.2 172 18 311 501 
a) MACS, Multicenter AIDS cohort study; CHAVI, the Center for HIV/AIDS Vaccine Immunology cohort; MAHS, Malawi Award for Human Settle-
ments cohort; WHIN, Women’s HIV Interdisciplinary Network cohort; SPIC, Seattle primary infection cohort; MGH, Massachusetts General Hospital co-
hort. 














Sn (%) Sp (%) Ac (%) Sn (%) Sp (%) Ac (%) 
MACS 79 5 74  100.0 81.1 87.8  60.0 98.6 96.2 
CHAVI 148 118 30  94.0 80.0 91.2  98.3 93.3 97.3 
WHIN, SPIC, MGH 49 2 47  100.0 85.1 85.7  100.0 91.5 91.8 
Others 148 35 113  92.8 74.7 79.0  91.4 92.0 91.9 
Total 424 160 264  94.4 78.8 84.7  95.6 93.9 94.6 
a) Window period is 200 days. 
 
Figure 1  Diversity versus infection duration for 424 subtype B samples. A, The diversity versus infection duration for 316 samples labeled with infection 
days and Fiebig Stages IV in the dataset of 424 samples. The sample points included in circle are false positive. B, The distributions of diversity values of 
total 424 samples included those marked with “late” (more than two years after seroconversion). C, The distribution of CV values of 424 samples. D, ROC  
curve of distinguishing recent and chronic infections. 
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be used to correctly exclude chronic infections (Figure 1C). 
Thus, CV=0.95 (mean value plus 3 folds of the standard 
deviation of the chronic infection) was used as cutoff to 
exclude chronic infections as the first step before using the 
average diversity for further identification. Any sample with 
a CV value larger than 0.95, without regard to its diversity 
value, was identified as a recent infection.   
To show the success of our method in identifying recent 
from chronic infections, we carried out the receiver operat-
ing characteristics (ROC) analysis over the whole subtype B 
database; the area under the ROC curve was 0.97 (Figure 
1D). The diversity value of 0.24 was selected as the best 
cutoff to distinguish recent from chronic infections. We 
correctly identified 153 in 160 (95.6%) recent infection, 
including 30 of 32 samples from multiple infection founders, 
and 248 in 264 (93.9%) chronic infections, overall, the accu-
racy was 94.6% for the individual carriers/patients (Table 2).  
The change of window period barely affected the per-
formance of our method. We have used different window 
periods to classify recent versus chronic infections. When 
the window periods were varied from 150 to 350 d, their 
accuracy rates ranged from 90% to 95% (Figure 2).  
For comparison, the alignment-based diversity of each 
sample was calculated using the CLUSTALW [20] and 
PHYLIP [21]. The mean values (standard deviation) were 
D0=0.01 (S0=0.02) for the recent infections, D1=0.08  
 
 
Figure 2  Window period versus accuracy of 424 sample dataset. As the 
window period ranges from 150 to 350 days, accuracy of our method var- 
ies from 90% to 95%. 
(S1=0.04) for chronic infections. When the value of 0.045 
was used as cutoff, the accuracy was about 84.6% (Table 2), 
showing that our method has a big advantage over the 
alignment-based method.  
The identification performance over the sub-dataset from 
different cohorts shows that the accuracy (97.3%) of the 
Center for HIV/AIDS Vaccine Immunology (CHAVI) pro-
ject was clearly higher than that of the others (91.9%). The 
higher accuracy derived from the CHAVI Project could be 
due to its higher stringency for the definition of seroconver-
sion with shorter sampling intervals. In all, the accuracies of 
our method in different cohorts were above 91%. Therefore, 
our method is less influenced by different populations. 
2.2  Identifying recent infection in the CRF07_BC da-
taset 
Applying our method to the CRF07_BC database, with a 
window period of one year, we identified 17 in 21 (80.9%) 
as recent infections and 52 in 56 (92.8%) as chronic infec-
tions. Overall, the accuracy was 89.6% (Table 3), almost 
equal to that in the subtype B dataset (with one year as the 
window period). 
For comparison, we have also applied the BED assay to run 
over the CRF07_BC dataset. The BED method identified 15 
in 21 (71.4%) as recent infections and 45 in 56 (80.3%) as 
chronic infections. Overall, the accuracy was 77.9% (Table 
3). 
2.3  Determination of recent infections and the minimal 
size of the dataset for estimating HIV incidence 
HIV incidence is estimated by using statistical approaches 
with adjustment from the recent infection rate of a sample 
collection extrapolating to the population level [1]. Using eq. 
(8) requires all the accuracy parameters of the assay method 
measurable, and the higher the accuracy of the assay meth-
od, the smaller the uncertain interval of the adjusted recent 
infection. The number of recent infections in the subtype B 
dataset was estimated by eq. (4) to be 160±13 (95% CI), 
suggesting that our method can be used to estimate the 
number of recent infections from a sample collection with 
high accuracy (100%) and accepted uncertain interval (8%). 
By incorporating incidence, estimated in the US population   





Sn (%) Sp (%) Ac (%) Method 
Recent Chronic 





21 56 81.0 92.9 89.6 This work 
21 56 71.4 80.3 77.9 BED* 
a) Window period is 365 days. *, The parameters measuring accuracy of BED method are calculated with widow period of 365 d. If calculated with a 
window period of 170 d, the parameters measuring accuracy of BED method are sensitivity (Sn)=89%, specificity (Sp)=73%, and accuracy (Ac)=75%. 
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in 2006 (about 0.3) [1] and PPV=0.905, NPV=0.973, re-
spectively, into eq. (8), the sample size required for esti-
mating the number of recent infections with 10% relative 
uncertain interval (95% CI) was about 300, and with 5% 
about 600. 
3  Discussion 
Prior to the XVIII International AIDS Conference in 2010, 
Science magazine published an editorial entitled “AIDS 
Response at a Crossroad”. This article pointed out that giv-
en the situation that there is no cure for AIDS and no vac-
cine for HIV prevention, lack of accurate ways to distin-
guish recent from chronic HIV infection at the individual or 
population levels is one of the three major obstacles in un-
derstanding the trends of the HIV/AIDS epidemic and mo-
bilizing a successful global HIV/AIDS control campaign 
[22]. Timely identification of such strategic information is 
key for global and national AIDS prevention programs to 
allocate resources and coordinate successful control 
measures to stop the epidemic [23].  
Several serological methods were used to address the is-
sues with some success. In serological assays, infected peo-
ple have different windows in producing HIV-specific anti-
bodies, ranging from two to twelve months [4]. In other 
words, some infected people exhibit high titer of antibody 
as early as within two months, and hence can be misjudged 
as chronic infections. Conversely, some chronic carriers can 
have lowered or even “disappeared” antibody levels in their 
blood, and can be mistakenly judged as recent infections. 
The broader problem for the serological assays is lack of not 
only reliable knowledge about the relationship between as-
say specificity and infection duration [24], but also infor-
mation on the window periods of immunological response 
for different HIV subtypes and population groups [4]. 
It was found in the recent systematic reviews in the field 
by the WHO Working Group on HIV Incidence-Assays and 
academia [1,2] that even though the serology-based assays 
have reasonable sensitivity, they are vulnerable to misclas-
sifying established HIV infection as recent ones. Because of 
high false-positive rates in patients with advanced infection 
or in ART treatment, UNAIDS still hesitates to recommend 
their use in routine surveillance. 
Compared with the serological assays, our new method 
has an advantage with high-accuracy; distinguishing the 
recent infections from the chronic ones and a low false- 
positive rate. 98.5% of 136 samples from patients infected 
more than 8 years (average incubation period) were cor-
rectly identified, whereas only 89.1% of 128 samples from 
patients infected 200 d8 years were correctly identified. It 
is shown that all false positives occur within four year after 
seroconversion, see Figure 1A. Furthermore, our method 
can provide a highly accurate identification of recent and 
long-term infections with a window period of up to one year 
instead of the ~160200 d window cutoff used in the BED 
method, which has the advantage of choosing a suitable 
window period to ensure that new infections are not missed. 
In addition, it is shown that our method is less affected by 
viral loads, host response, and treatment. 
A widely used method, referred to as alignment-based 
viral sequences analysis, has been used for estimating the 
origin and history of the HIV-1 epidemic [2022]. However, 
this method is particularly problematic for analyzing genes 
such as the env gene, which actively undergoes variations, 
including insertions and deletions. Pair-wise distance de-
fined by the alignment-based method depends on the relia-
bility of sequence alignments. However, since the gap pen-
alty is chosen by experience, alignment results are variable. 
By contrast, our pattern-based distance gives nearly identi-
cal values to different evolutionary events, such as point 
mutations, insertions, and deletions [23]. In preparation for 
our manuscript, Park et al. published an HIV incidence as-
say using the alignment-based env gene diversity [25]. The 
accuracy of their method was as high as that of our method, 
but they used a small and biased dataset containing 182 re-
cent and 43 chronic cases. Using a larger dataset (424 cases) 
with the recent to chronic ratio close to the real situation 
(about 0.3 [1] ), our results show that the accuracy of the 
assay using alignment-based diversity is much lower than 
that of the pattern-based one described in this study. The 
coefficients of variation (standard deviation/mean) of the 
alignment-based and pattern-based approaches are 2.44 and 
1.37 for recent infections, and 0.54 and 0.41 for long- 
standing infection, respectively, showing that the measure-
ment constructed in the pattern-based approach is more sen-
sitive and reliable than the alignment-based approach for 
identification of recent infection. 
This method uses the viral env sequence to identify re-
cent infection. In actual application, it is important to ensure 
that the sequences of a sample are representative of HIV-1 
populations in vivo. This experimental procedure is labor 
intensive and difficult in application in large scale. Fortu-
nately, owing to the advent of automation technology, gen-
erating sequences from blood samples has become much 
faster, easier and cheaper than ever before. In the course of 
adopting the automation technology, we have modified it 
into an automated liquid handling workstation, and were 
able to overcome the rate-limiting step in attaining accurate 
viral sequences. Furthermore, samples collected in re-
source-limited areas could be analyzed in a well-established 
laboratory through international collaboration.   
Recently, systematic reviews of the fields of serolo-
gy-based HIV measuring assays were conducted by the 
WHO Working Group on HIV Incidence-Assays and aca-
demia. Both reviews concluded that there is an urgent need 
to improve the current serology-based HIV incidence assays, 
and the solution should come from combined approaches of 
complimentary methodology using vinous biomarkers [1,2]. 
There is much diversity in the level of global HIV/AIDS 
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epidemics; the adult HIV prevalence ranging from a high of 
up to 30% in some African countries to as low as 0.01% in 
Europe and middle-eastern countries. The annually reported 
HIV/AIDS cases are also varied widely in national surveil-
lance of different countries, from just a few hundreds to 
hundreds of thousands. Therefore, various countries in the 
high and low HIV epidemic regions can selectively use se-
rology-based or pattern-based genetic diversity methods 
according to the purpose of their surveillance needs. In fact, 
the China CDC has begun to test the combined use of both 
BED and the pattern-based genetic diversity method in the 
field to accurately evaluate the recent HIV infection and 
monitor AIDS epidemic trends as well, in both high and low 
epidemic regions in China. 
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